1 Associations of Combined Phenotypic Aging and Genetic Risk with Incident

2 Cancer: A Prospective Cohort Study

- 3
- 4 Lijun Bian^{1,2†}, Zhimin Ma^{1†}, Xiangjin Fu¹, Chen Ji¹, Tianpei Wang¹, Caiwang Yan^{1,2,3},
- Juncheng Dai^{1,2}, Hongxia Ma^{1,2}, Zhibin Hu^{1,2}, Hongbing Shen^{1,2,4}, Lu Wang^{3*}, Meng
 Zhu^{1,2,3*}, Guangfu Jin^{1,2,3*}
- 7
- ¹ Department of Epidemiology, Center for Global Health, School of Public Health,
- 9 Nanjing Medical University, Nanjing, China.
- ² Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
- 11 Innovation Center for Cancer Personalized Medicine and China International
- 12 Cooperation Center for Environment and Human Health Nanjing Medical University,
- 13 Nanjing, China.
- ³ Department of Chronic Non-Communicable Disease Control, The Affiliated Wuxi
- 15 Center for Disease Control and Prevention of Nanjing Medical University, Wuxi
- 16 Center for Disease Control and Prevention, Wuxi Medical Center, Nanjing Medical
- 17 University, Wuxi, China.
- ⁴ Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese
- 19 Academy of Medical Sciences, Beijing, China.
- 20
- [†]These authors contributed equally to this work.
- ²² **Correspondence to:** Prof Guangfu Jin, Department of Epidemiology, Center for
- 23 Global Health, School of Public Health, Nanjing Medical University, 101 Longmian
- Rd., Nanjing 211166, China. Email: guangfujin@njmu.edu.cn; or Prof Meng Zhu,
- 25 Department of Epidemiology, Center for Global Health, School of Public Health,
- 26 Nanjing Medical University, 101 Longmian Rd., Nanjing 211166, China. E-mail:

- 27 zhmnjmu@njmu.edu.cn; or Prof Lu Wang, Department of Chronic
- 28 Non-Communicable Disease Control, Wuxi Center for Disease Control and
- 29 Prevention, Affiliated Wuxi Center for Disease Control and Prevention of Nanjing
- 30 Medical University, 499 Jincheng Rd., Wuxi 214023, China. E-mail:
- 31 wanglu123@njmu.edu.cn.

32 Abstract

33 Background

- 34 Age is the most important risk factor for cancer, but aging rates are heterogeneous
- across individuals. We explored a new measure of aging-Phenotypic Age
- 36 (PhenoAge)-in the risk prediction of site-specific and overall cancer.

37 Methods

- 38 Using Cox regression models, we examined the association of Phenotypic Age
- 39 Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among
- 40 374,463 participants from the UK Biobank. We generated PhenoAge using
- 41 chronological age and 9 biomarkers, PhenoAgeAccel after subtracting the effect of
- 42 chronological age by regression residual, and an incidence weighted overall cancer
- 43 polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores
- 44 (PRSs).

45 **Results**

- 46 Compared with biologically younger participants, those older had a significantly
- 47 higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence
- 48 interval, 1.18-1.27) in men, 1.26 (1.22-1.31) in women, respectively. A joint effect of
- 49 genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of
- 50 2.29 (2.10-2.51) for men and 1.94 (1.78-2.11) for women with high genetic risk and
- older PhenoAge compared with those with low genetic risk and younger PhenoAge.
- 52 PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors
- 53 (Beta = -1.01 in men, P < 0.001; Beta = -0.98 in women, P < 0.001).

54 Conclusions

Within and across genetic risk groups, older PhenoAge was consistently related to an
increased risk of incident cancer with adjustment for chronological age and the aging
process could be retarded by adherence to a healthy lifestyle.

58 Key Words: Phenotypic aging; Polygenic risk score; Healthy lifestyle; Cancer risk.

59 Introduction

60 Cancer continues to be the leading cause of death globally and the reduction of 61 cancer-related deaths remains to be a public health priority (Bray et al., 2018). The 62 morbidity and mortality of cancer increase dramatically with age, which demonstrated 63 that aging is the greatest risk factor for cancer (Siegel, Miller, & Jemal, 2018). 64 Although everyone gets older, individuals are aging at different rates (Rutledge, Oh, 65 & Wyss-Coray, 2022). Therefore, the variation in the pace of aging between-person 66 may reflect the differences in susceptibility to cancer and death. Thus, measurement 67 of an individual's biological age, particularly at the early stage of life, may promote 68 the primary and secondary prevention of cancer through earlier identification of high 69 risk groups. 70 Recently, Morgan and colleagues developed and validated a novel multi-system-based 71 aging measurement (Levine et al., 2018), Phenotypic Age (PhenoAge), which has 72 been shown to capture long-term vulnerability to diseases like COVID-19, and 73 strongly predict morbidity and mortality risk in diverse populations (Kuo, Pilling, 74 Atkins, et al., 2021; Liu et al., 2018). However, it is largely unknown whether 75 PhenoAge can predict overall cancer risk and identify high risk individuals for 76 potential personalized prevention. 77 To date, more than 2,000 genetic loci have been identified as susceptibility markers 78 for certain cancers by genome-wide association studies (GWAS) (Buniello et al., 79 2019). Although the effect of these individual loci is relatively modest on cancer risk, 80 a polygenic risk score (PRS) combining multiple loci together as an indicator of 81 genetic risk has been proved to effectively predict incidence of site-specific cancer 82 (Dai et al., 2019; Lecarpentier et al., 2017; Mars et al., 2020). Recently, we 83 systematically created site-specific cancer PRS for 20 cancer types, and constructed 84 an incidence-weighted cancer polygenic risk score (CPRS) to assess the effect of 85 genetic risk on overall incident cancer risk based on the UK Biobank (Zhu et al.,

86 2021). Previous study had indicated an interaction between genetic factor and age on

87 cancer risk (Mavaddat et al., 2015). However, the extent to interaction between

88 genetic factor and PhenoAge on overall cancer risk remained unclear.

In this study, we calculated PhenoAge in accordance with the method described previously and then evaluated the effectiveness of PhenoAge in predicting risk of overall cancer in the UK Biobank. We also assessed the extent to which a level of accelerated aging was associated with an increased overall cancer risk across groups with a different genetic risk defined by the CPRS.

94

95 Methods

96 **Participants**

97 The participants included in this study are derived from the UK Biobank. The UK 98 Biobank is a large population-based cohort study and detail protocol is publicly 99 available (Bycroft et al., 2018). In brief, approximately 500,000 participants aged 100 40-70 were recruited from 22 assessment centers across England, Scotland, and Wales 101 between 2006 and 2010 at baseline. Each eligible participant completed a written 102 informed consent form and provided information on lifestyle and other potentially 103 health-related aspects through extensive baseline questionnaires, interviews, and 104 physical measurements. Meanwhile, biological samples of participants were also 105 collected for biomarker assays and a blood draw was collected for genotyping. The 106 UK Biobank study has approval from the Multi-center Research Ethics Committee, 107 the National Information Governance Board for Health and Social Care in England 108 and Wales, and the Community Health Index Advisory Group in Scotland 109 (http://www.ukbiobank.ac.uk/ethics/).

110 PhenoAge and PhenoAgeAccel PRS

111 We calculated PhenoAge in accordance with the method described previously (Levine

et al., 2018). Briefly, PhenoAge was calculated based on mortality scores from the

113 Gompertz proportional hazard model on chronological age and 9 multi-system clinical

- 114 chemistry biomarkers (albumin, creatinine, glucose, [log] C-reactive protein [CRP],
- 115 lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline
- 116 phosphatase, and white blood cell count) to predict all-cause mortality. The
- 117 Biomarkers in the UK Biobank were measured at baseline (2006-2010) for all
- 118 participants. To correct distribution skewness, we set the top and bottom 1% of values
- to the 99th and 1st percentiles. The formula of PhenoAge is given by

PhenoAge = 141.50 +
$$\frac{\ln\left\{(-0.00553) \times \frac{(-1.51714) \times \exp(xb)}{0.0076927}\right\}}{0.09165}$$

120 where

 $xb = -19.907 - 0.0336 \times \text{albumin} + 0.0095 \times \text{creatinine} + 0.1953 \times \text{glucose}$ $+ 0.0954 \times \ln(\text{CRP}) - 0.0120 \times \text{lymphocytepercentage} + 0.0268$ $\times \text{ mean corpuscular volume} + 0.3306$ $\times \text{ red blood cell distribution width}(\text{RDW}) + 0.00188$ $\times \text{ alkaline phosphatase} + 0.0554 \times \text{white blood cell count}$ $+ 0.0804 \times \text{age}$

121

122 Finally, we calculated Phenotypic Age Acceleration (PhenoAgeAccel), which was 123 defined as the residual resulting from a linear model when regressing Phenotypic Age 124 on chronological age. Therefore, PhenoAgeAccel represents Phenotypic Age after 125 accounting for chronological age (i.e., whether a person appears older [positive value] 126 or younger [negative value] than expected, biologically, based on his/her age). 55 independent PhenoAgeAccel-associated SNPs ($P < 5 \times 10^{-8}$) and corresponding 127 128 effect sizes were derived from a large-scale PhenoAgeAccel GWAS including 129 107,460 individuals of European ancestry (Kuo, Pilling, Liu, Atkins, & Levine, 2021). A PhenoAgeAccel PRS was created using an additive model as previously described 130 (Dai et al., 2019). In short, the genotype dosage of each risk allele for each individual 131

132 was summed after multiplying by its respective effect size of PhenoAgeAccel.

133 PRS calculation and CPRS construction

134 The calculation of site-specific cancer PRSs and the construction of CPRSs have been 135 described in our previous published study (Zhu et al., 2021). In brief, for individual 136 cancer, risk associated single nucleotide polymorphisms (SNPs) and corresponding 137 effect sizes were derived from the largest published GWASs in terms of sample size. 138 Next, the dosage of each risk allele for each individual was summed after 139 multiplication with its respective effect size of site-specific cancer. Except for 140 non-melanoma skin cancer and those without relevant GWAS or significant genetic 141 loci published by now, we derived PRSs for 20 cancer types in this analysis. To 142 generate an indicator of genetic risk for overall cancer, we constructed the CPRS as 143 follows:

$$CPRS_i = \sum_{k=1}^{K} h_k PRS_{i,k}$$

144 Where $CPRS_i$ is the cancer polygenic risk score of ith individual, h_k is the 145 age-standardized incidence of site-specific cancer k in UK population, and $PRS_{i,k}$ is 146 the aforementioned PRS of site-specific cancer k. Given the different spectrum of 147 cancer incidence between men and women, CPRS were constructed for males and 148 females, respectively.

149 Assessment of healthy lifestyle

150 We adopted five healthy lifestyle factors according to the World Cancer Research

151 Fund/American Institute of Cancer Research recommendations

152 (https://www.aicr.org/cancer-prevention/) (Shams-White et al., 2019), i.e., no current

- smoking, no alcohol consumption, regular physical activity, moderate BMI
- 154 (body-mass index, 18.5~30), and a healthy diet pattern. Participants of no current
- smoking were defined as never smoker or former smokers who had quit smoking at
- 156 least 30 years. No alcohol consumption was defined as never alcohol use. Regular
- 157 physical activity was defined as at least 75 minutes of vigorous activity per week or

158 150 minutes of moderate activity per week (or an equivalent combination) or

159 engaging in vigorous activity once and moderate physical activity at least 5 days a

160 week (Lourida et al., 2019). A healthy diet pattern was ascertained consumption of an

161 increased amount of fruits, vegetables, whole grains, fish and a reduced amount of red

meats and processed meats (Lourida et al., 2019). The lifestyle index ranged from 0 to

163 5, with higher index indicating a healthier lifestyle.

164 Outcomes

165 Outcomes of incident cancer events in the UK Biobank were ascertained through

record electronic linkage with the National Health Service central registers and death

registries in England, Wales and Scotland. Complete follow-up was updated to 31

168 October 2015 for Scotland, and to 31 March 2016 for England & Wales. Cancer

events were coded using the 10^{th} Revision of the International Classification of

170 Diseases. The outcome of all cancer events were obtained from data field 40006 and

171 40005 of the UK Biobank.

172 Statistical analysis

173 Cancer risk of participants in the UK Biobank was assessed from baseline until to the 174 date of diagnosis, death, loss to follow-up, or date of complete follow-up, whichever 175 occurred first. Multivariable Cox proportional hazards regression analyses were 176 performed to assess associations between PhenoAgeAccel and cancer risk and to 177 estimate hazard ratios (HRs) as well as 95% confidence intervals (CI). Schoenfeld 178 residuals and log-log inspection were used to test the assumption of proportional hazards. HRs associated with per 5 years increased of PhenoAgeAccel was calculated 179 180 for site-specific cancer and overall cancer respectively. We compared HRs between 181 biologically younger and older participants. In addition, we calculated HRs for 182 participants at low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 183 2-4), and high (the top quintile) accelerated aging, and HRs for participants splitted by decile of accelerated aging. 184

185 Meanwhile, participants were also divided into low (the bottom quintile of CPRS),

186 intermediate (quintiles 2-4), and high (the top quintile) genetic risk groups. Absolute 187 risk within each subgroup defined by PhenoAgeAccel and CPRS were calculated as 188 the percentage of incident cancer cases occurring in a given group. We calculated 189 absolute risk increase as the difference in cancer incidences among given groups, 190 extrapolated the difference in 5-year event rates among given groups. The 95% CIs 191 for the absolute risk increase were derived by drawing 1,000 bootstrap samples from 192 the estimation dataset. We performed additive interaction analysis between genetic 193 risk (defined by CPRS) and PhenoAgeAccel on overall cancer risk, as well as genetic 194 risk (defined by PhenoAgeAccel PRS) and lifestyle on PhenoAgeAccel using two 195 indexes: the relative excess risk due to interaction (RERI) and the attributable 196 proportion due to interaction (AP) (R. Li & Chambless, 2007). The 95% CIs of the 197 RERI and AP were estimated by bootstrap (N = 5,000), which would contain 0 if there 198 was no additive interaction. We also used multivariable linear regression models to 199 assess associations between the PhenoAgeAccel and individual lifestyle factors with 200 adjustment for age, family history of cancer, Townsend deprivation index, height, and 201 the first 10 principal components of ancestry. All the above mentioned analyses were 202 performed for men and women separately.

203 Participants with missing data on any of the covariates were multiple imputed, and 204 independent analyses were also performed based on complete data for sensitivity 205 analyses. Besides, to examine the reliability of our results, we conducted several 206 sensitivity analyses: (1) reclassifying PhenoAgeAccel levels based on quartiles 207 (bottom, 2-3, and top quartiles defined as low, intermediate, and high accelerated 208 aging, respectively) or tertiles (corresponding to low, intermediate, and high 209 accelerated aging) of PhenoAgeAccel; (2) reevaluating the effect of PhenoAgeAccel 210 based on participants of unrelated British ancestry; (3) excluding incident cases of any 211 cancer occurring during the two years of follow-up; and (4) retrained PhenoAge in 212 cancer-free participants based on mortality. All P values were two-sided and P < 0.05213 was considered statistically significant. All statistical analyses were performed with R 214 software, version 3.6.3 (R Project for Statistical Computing).

215

216 **Results**

217 **Participants**

218 After removing participants who had withdrawn their consent, had been diagnosed

- 219 with cancer before baseline, failed to be genotyped, reported a mismatch sex with
- 220 genetic data, or with missing data on PhenoAge, the final analytic dataset included
- 221 374,463 eligible participants (173,431 men and 201,032 women). Of which, 169,573
- participants were biologically older, with 92,189 men and 77,384 women, whose
- median PhenoAgeAccel were 3.28 (interquartile range [IQR]: 1.50 to 6.06) and 3.07
- (IQR: 1.33 to 5.79) respectively; 204,890 participants were biologically younger, with
- 81,242 men and 123,648 women, whose median PhenoAgeAccel were -2.61 (IQR:

-4.35 to -1.25) and -3.55 (IQR: -5.64 to -1.81) respectively (**Table 1, Appendix**

227 **1-figure 1**).

228 Associations of PhenoAgeAccel with cancer risk

There were 22,370 incident cancer cases, with 11,532 men and 10,838 women, during

a median follow-up of 7.09 years (IQR: 6.35 to 7.72). The PhenoAgeAccel was

significantly associated with increased risk for cancer sites of lip-oral cavity-pharynx,

esophagus, stomach, colon-rectum, pancreas, lung, breast, cervix uteri, corpus uteri,

233 prostate, kidney, bladder, multiple myeloma, Hodgkin's disease, and lymphoid

leukaemia, while negatively associated with risk of prostate cancer after adjusting for

chronological age and other covariates (Figure 1, Appendix 1-table 1).

For overall cancer, we observed an obviously higher distribution of PhenoAgeAccel

in incident cancer cases than participants without incident cancer in both men and

- women (Figure 2A and B). PhenoAgeAccel was significantly associated with an
- 239 increased risk of overall cancer in men (HR = 1.15, 95% CI, 1.13-1.17, P < 0.0001)
- and women (HR = 1.15, 95% CI, 1.13-1.17, P < 0.0001) per 5 years increase (**Table**
- 241 2). We also observed a significantly gradient increase in incident cancer risk from
- decile 1 to decile 10 of PhenoAgeAccel (Figure 2C and D). Compared with

243	biologically	vounger partic	ipants, those	older had a	a significant	ly higher	risk of o	verall
						1 (7 -		

cancer, with HRs of 1.22 (95% CI, 1.18-1.27, P < 0.0001) in men, 1.26 (95% CI,

- 1.22-1.31, P < 0.0001) in women, respectively (Figure 2E and F). Besides, Compared
- with individuals at low accelerated aging (the bottom quintile of PhenoAgeAccel),
- those in the intermediate (quintiles 2 to 4) and high accelerated aging (the top quintile)
- had a significantly higher risk of overall cancer, with HRs of 1.15 (95% CI, 1.09-1.21,
- 249 P < 0.0001) and 1.44 (95% CI, 1.36-1.53, P < 0.0001) in men, 1.15 (95% CI,
- 250 1.09-1.21, P < 0.0001) and 1.46 (95% CI, 1.38-1.55, P < 0.0001) in women,
- 251 respectively. These results did not change after adjustment for genetic risk and
- 252 lifestyle factors (Table 2). Similar patterns were noted in a series of sensitivity
- analyses with reclassifying accelerated aging levels according to quartiles or tertiles
- of the PhenoAgeAccel (Appendix 1-table 2), exclusion of incident cancer cases
- occurred during the two years of follow-up (**Appendix 1-table 3**), in the unimputed
- data (Appendix 1-table 4), in the unrelated British population (Appendix 1-table 5),
- 257 or using retrained PhenoAge in cancer-free participants (Appendix 1-table 6).

Joint effect and interaction of genetic factor and PhenoAgeAccel on overall

259 cancer risk

260 The overall incident cancer risk associated with both genetic risk and PhenoAgeAccel

in a dose-response manner (Figure 3). Of participants with high genetic risk and older

262 PhenoAge, the incidence rates of overall cancer per 100,000 person-years were

estimated to be 1477.89 (95% CI, 1410.87-1544.92) in men and 1076.17 (95% CI,

264 1014.14-1138.19) in women versus 581.06 (95% CI, 537.12-625.00) in men and

265 594.71 (95% CI, 558.50-630.92) in women with low genetic risk and younger

- 266 PhenoAge. Approximate double risks [HR, 2.29 (95% CI, 2.10-2.51) in men, P <
- 267 0.0001; 1.94 (95% CI, 1.78-2.11) in women, P < 0.0001] were observed in
- 268 participants with high genetic risk and older PhenoAge, compared with those with
- low genetic risk and younger PhenoAge. Similar patterns were noted by reclassifying
- accelerated aging levels into low (the bottom quintile of PhenoAgeAccel),
- intermediate (quintiles 2-4), and high (the top quintile) (**Appendix 1-figure 2**).

272 However, we did not observe interaction between genetic and PhenoAgeAccel on

273 overall cancer risk in men and women (**Appendix 1-table 7**).

274 Disadvantages of older PhenoAge with overall incident cancer

In further stratification analyses by genetic risk category with younger PhenoAge as the reference group, we confirmed that older PhenoAge was significantly associated with a higher incident cancer risk across genetic risk groups (**Table 3**). Among participants at high genetic risk, the standardized 5-year incident cancer rates were 5.78% and 4.58% for biologically younger men and women versus 6.90% and 5.17% for those older, respectively. Similarly, among participants at low genetic risk, the

standardized 5-year incident cancer rates increased from 2.71% and 2.83% for

biologically younger to 3.87% and 3.39% for those older in men and women,

respectively. Similar patterns were noted by reclassifying accelerated aging levels into

- low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high
- (the top quintile) (**Appendix 1-table 8**).

In addition, to evaluate the implication for cancer screening in populations with

different PhenoAgeAccel, we estimated the 5-year absolute risk of overall cancer

between biologically younger and older participants with the increasing of age.

Assuming 2% of absolute risk within the next 5 years as the threshold to be

recommended for cancer screening, biologically younger men would reach the

threshold at age 52, whereas those older men would reach the threshold at age 50;

similarly, biologically younger women would reach the 2% of 5-year absolute risk at

age 46, whereas those older women would reach the threshold at age 44 (**Figure 4**).

294 Associations of lifestyle factors with PhenoAgeAccel

- In the UK Biobank, biologically younger men (9.6%, 7,781/81,242) and women
- (14.4%, 17,781/123,648) were more likely to have favorable lifestyle (4 to 5 healthy
- lifestyle factors) than older men (5.7%, 5,255/92,189) and women (9.3%,
- 298 7,178/77,384) (**Table 1**). Among both men and women, we observed that
- 299 PhenoAgeAccel decreased with the increase of healthy lifestyle factors (Appendix

1-table 9). In addition, we found a significant negative correlation between the

number of healthy lifestyle factors and PhenoAgeAccel (Beta = -1.01 in men, P < -1.01

302 0.001; Beta = -0.98 in women, P < 0.001) (Appendix 1-table 10). However, we did

not observe any interaction between genetic risk and lifestyle on PhenoAgeAccel in

- 304 both men and women (**Appendix 1-table 11**).
- 305

306 Discussion

In this study, we calculated PhenoAgeAccel to explore the effect of accelerated aging 307 308 on the risk of cancer, and demonstrated a positive association between accelerated 309 aging and increased cancer risk after adjustment for chronological age in the UK 310 Biobank. Meanwhile, older PhenoAge was consistently associated with an increased 311 absolute risk of incident cancer within each genetic risk group; and participants with 312 high genetic risk and older PhenoAge had the greatest incident cancer risk. Therefore, 313 our findings provided the evidence for PhenoAgeAccel to be used for risk 314 stratification of cancer, which were independent from genetic risk. Moreover, we also 315 demonstrated that participants with older biological age often reaches the screening 316 threshold 2 years in advance compared with biologically younger peers; and keeping a 317 healthy lifestyle can effectively slow down the aging process. 318 Older age has been long recognized as the main risk factor for cancer, and the 319 multistage model of carcinogenesis posits that the exponential increase in cancer 320 incidence with age were mainly resulted from the sequential accumulation of 321 oncogenic mutations in different tissues throughout life (Laconi, Marongiu, & 322 DeGregori, 2020). In consistent with this, age and exposure (i.e. smoking, ultraviolet

light) dependent mutation signatures have been identified in several cancers by tissue

sequencing (Alexandrov et al., 2020). However, biological aging is an enormously

325 complex process and is thought to be influenced by multiple genetic and

environmental factors (van Dongen et al., 2016). Therefore, several biomarkers, i.e.

327 'ageing clocks' derived from epigenomic, transcriptomic, proteomic and metabolomic

data, have been proposed to measure the biological age and predict risk of cancer and
other diseases (Rutledge et al., 2022; Zhang et al., 2022). However, these measures
were usually based on omics data and was not suitable for application in large
population by now. As a result, results from this study would provide a cost-effective
indicator for measuring of biological age as well as a novel biomarker for cancer risk
prediction.

334 The associations between biological age and cancer risk has been investigated by 335 several studies recently. Li et al. explored three DNA methylation phenotypic age and 336 cancer risk in four subsets of a population-based cohort from Germany, and reported 337 strong positive associations for lung cancer, while strong inverse associations for 338 breast cancer (X. Li, Schottker, Holleczek, & Brenner, 2022). Meanwhile, results 339 from Melbourne Collaborative Cohort Study reported that epigenetic aging was 340 associated with increased cancer risk of kidney cancer and B-cell lymphoma (Dugue 341 et al., 2018). However, because of sample size, the association results were still 342 inconsistent for DNA methylation phenotypic age among different studies. Leukocyte 343 telomere length was also significantly associated with age and were regarded as an 344 indicator of aging. Based on data from the UK Biobank, Schneider et al. recently 345 explored the associations between telomere length and risk of several disease, and 346 reported significant positive associations of telomere length for lymphoid leukemia, 347 multiple myeloma, non-Hodgkin lymphoma, esophagus cancer, while negative 348 associations for malignant neoplasm of brain, mesothelioma, and melanoma 349 (Schneider et al., 2022). The positive associations were in consistent with our findings, 350 however, the negative associations were not significant in our study. Meanwhile, the 351 study did not indicate associations for other cancers, including cancers of lung, 352 stomach, pancreases, and kidney, which showed relatively large effects (HR > 1.3) in 353 our study. These findings indicated that the different measures of biological age may 354 reflect the different aspects of aging, and could be joint application in cancer risk 355 assessment.

356 Recently, several studies have confirmed the associations between PhenoAgeAccel

357 and cancer risk. Mak et al. explored three measures of biological age, including 358 PhenoAge, and assessed their associations with the incidence of overall cancer and 359 five common cancers (breast, prostate, lung, colorectal, and melanoma) (Mak et al., 360 2023). In our previous study, we investigated the association between PhenoAgeAccel 361 and lung cancer risk and analyzed the joint and interactive effects of PhenoAgeAccel and genetic factors on the risk of lung cancer (Ma et al., 2023). In comparison to these 362 363 studies, our analysis expanded the range of cancers to 20 types and further explored 364 the associations in different genetic and lifestyle contexts. Moreover, we also 365 evaluated the potential implications of PhenoAge in population-level cancer screening. 366 In addition, we observed a negative association between PhenoAgeAccel and prostate 367 cancer risk. The unexpected association may have been confounded by diabetes and 368 altered glucose metabolism, both of which are closely linked to aging. When we 369 removed HbA1c and serum glucose from the biological age algorithms, the 370 association became non-statistically significant. Similar findings were also reported 371 by Mak et al. (Mak et al., 2023) and Dugue et al. (Dugue et al., 2021). The associations between PhenoAgeAccel and increased cancer risk may be partly 372 373 attribute to a result of decline in the immune system and accumulation of 374 environmental carcinogenic factors. Recent GWASs of PhenoAgeAccel showed that SNPs associated with PhenoAgeAccel were enriched in pathways of immune system 375 376 and activation of pro-inflammatory (Kuo, Pilling, Liu, Atkins, & Levine, 2021; 377 Levine et al., 2018). In addition to genetics, behaviors (i.e. obesity, smoking, alcohol 378 consumption, and physical activity), and life course circumstances (i.e. 379 socioenvironmental circumstances during childhood and adulthood) were reported to 380 account for about 30% variances of phenotypic aging (Liu et al., 2019). This was in 381 accordance with our findings that, adherence to healthy lifestyles (involving no 382 current smoking, normal BMI, regular physical activity, and healthy diet) could slow 383 down the aging process. In other words, these healthy lifestyles considered in our and 384 previous studies may be causal drivers of phenotypic aging, they represent a more 385 targetable strategy for reducing overall cancer burden by retarding the aging process.

Therefore, PhenoAge provide a meaningful intermediate phenotype that can be used
to guide interventions for high risk groups and track intervention efficacy (Liu et al.,
2019).

389 This study has several strengths, including a large sample size, a prospective design of 390 the UK Biobank study, and an effective application of PhenoAgeAccel in predicting 391 risk of overall cancer. Nevertheless, we also acknowledge several limitations. First, 392 we calculated PhenoAge based on 9 biomarkers from blood, which were measured at 393 baseline. As such, we were unable to access the change of PhenoAgeAccel during the 394 follow-up period. Second, previous studies have indicated that patricians in the UK 395 Biobank differ from the general UK population because of low participation and 396 healthy volunteer bias (Fry et al., 2017). Finally, even though the findings were 397 achieved from participants with diverse ethnic backgrounds of the UK Biobank, the 398 generalizability of our findings should be further assessed in more diverse populations 399 when available.

400 In summary, our study showed that accelerated aging, which was measured by

401 PhenoAgeAccel, was consistently related to an increased risk of several site-specific

402 cancer and overall cancer with adjustment for chronological age, within and across

403 genetic risk groups. PhenoAgeAccel can serve as a productive tool to facilitate

404 identification of cancer susceptible individuals, in combination with individual's

405 genetic background, and act as an intermediate phenotype to guide interventions for

406 high risk groups and track intervention efficacy.

407

Ethics approval and consent to participate: This research was conducted using the
UK Biobank Resource (Application Number: 60169). UK Biobank has received
ethics approval from the Research Ethics Committee (ref. 11/NW/0382).

411 Availability of data and materials: The data underlying the results presented in the
412 study are available from the UK Biobank (http://biobank.ndph.ox.ac.uk/showcase/).

413 **Competing interests:** The authors declare that they have no competing interests.

- 414 Funding: This work was supported by National Natural Science Foundation of China
- 415 (82230110, 82125033 to GJ; 82273714 to MZ); and the Excellent Youth Foundation
- 416 of Jiangsu Province (BK20220100 to MZ).

417 Authors' Contributions

- 418 **L. Bian**: Data curation, formal analysis, validation, visualization, writing–original
- 419 draft, writing–review and editing. **Z. Ma**: Data curation, formal analysis, validation,
- 420 visualization, writing–review and editing. **X. Fu**: Data curation, validation,
- 421 visualization, writing–review and editing. C. Ji: Data curation, validation,
- 422 visualization. T. Wang: Methodology, formal analysis, validation, visualization,
- 423 writing-review and editing. C. Yan: Methodology, writing-review and editing. J. Dai:
- 424 Methodology, writing–review and editing. **H. Ma**: Supervision, project administration,
- 425 writing-review and editing. Z. Hu: Conceptualization, supervision, project
- 426 administration, writing-review and editing. H. Shen: Conceptualization, resources,
- 427 supervision, project administration, writing–review and editing. **L. Wang**:
- 428 Conceptualization, formal analysis, supervision, validation, writing-review and
- 429 editing. M. Zhu: Conceptualization, formal analysis, supervision, funding acquisition,
- 430 validation, writing–original draft, writing–review and editing. **G. Jin**:
- 431 Conceptualization, formal analysis, supervision, funding acquisition, validation,
- 432 writing–review and editing.

433 Acknowledgments

- 434 The authors thank the investigators and participants in UK Biobank for their
- 435 contributions to this study.

436 **References**

- Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., . . . Consortium, P.
 (2020). The repertoire of mutational signatures in human cancer. *Nature*, *578*(7793), 94-101.
 doi: 10.1038/s41586-020-1943-3
- 440 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer
- statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
 185 countries. *CA Cancer J Clin, 68*(6), 394-424. doi: 10.3322/caac.21492
- 442 165 countries. CA cuncer 5 cnn, 66(6), 594-424. uoi. 10.5522/cad.21492
- Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., . . . Parkinson, H.
 (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies,

445 446	targeted arrays and summary statistics 2019. <i>Nucleic Acids Res, 47</i> (D1), D1005-D1012. doi:
117	Bycroft C Freeman C Petkova D Band G Elliott T Sharp K Marchini (2018) The IIK
448	Biobank resource with deep phenotyping and genomic data. <i>Nature, 562</i> (7726), 203-209. doi:
449	10.1038/s41586-018-0579-z
450	Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., Shen, H. (2019). Identification of risk loci and a
451	polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese
452	populations. <i>Lancet Respir Med, 7</i> (10), 881-891. doi: 10.1016/S2213-2600(19)30144-4
453	Dugue, P. A., Bassett, J. K., Joo, J. E., Jung, C. H., Ming Wong, E., Moreno-Betancur, M., Milne, R. L.
454	(2018). DNA methylation-based biological aging and cancer risk and survival: Pooled analysis
455	of seven prospective studies. Int J Cancer, 142(8), 1611-1619. doi: 10.1002/ijc.31189
456	Dugue, P. A., Bassett, J. K., Wong, E. M., Joo, J. E., Li, S., Yu, C., Milne, R. L. (2021). Biological Aging
457	Measures Based on Blood DNA Methylation and Risk of Cancer: A Prospective Study. JNCI
458	<i>Cancer Spectr, 5</i> (1). doi: 10.1093/jncics/pkaa109
459	Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Allen, N. E. (2017).
460	Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
461	Participants With Those of the General Population. Am J Epidemiol, 186(9), 1026-1034. doi:
462	10.1093/aje/kwx246
463	Kuo, C. L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Tignanelli, C., Levine, M. E. (2021).
464	Biological Aging Predicts Vulnerability to COVID-19 Severity in UK Biobank Participants. J
465	Gerontol A Biol Sci Med Sci, 76(8), e133-e141. doi: 10.1093/gerona/g ab060
466	Kuo, C. L., Pilling, L. C., Liu, Z., Atkins, J. L., & Levine, M. E. (2021). Genetic associations for two
467	biological age measures point to distinct aging phenotypes. <i>Aging Cell, 20</i> (6), e13376. doi:
468	10.1111/acel.13376
469	Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: changing mutational
470	and microenvironmental landscapes. <i>Br J Cancer, 122</i> (7), 943-952. doi:
471	10.1038/s41416-019-0721-1
472	Lecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., Ottini, L.
473	(2017). Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation
474	Carriers Using Polygenic Risk Scores. <i>J Clin Oncol, 35</i> (20), 2240-2250. doi:
475	10.1200/JCO.2016.69.4935
476	Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Horvath, S. (2018). An
477	epigenetic biomarker of aging for lifespan and healthspan. <i>Aging (Albany NY), 10</i> (4), 573-591.
478	doi: 10.18632/aging.101414
479	Li, R., & Chambless, L. (2007). Test for additive interaction in proportional hazards models. Ann
480	<i>Epidemiol, 17</i> (3), 227-236. doi: 10.1016/j.annepidem.2006.10.009
481	Li, X., Schottker, B., Holleczek, B., & Brenner, H. (2022). Associations of DNA methylation algorithms of
482	aging and cancer risk: Results from a prospective cohort study. <i>EBioMedicine, 81,</i> 104083. doi:
483	10.1016/j.ebiom.2022.104083
484	Liu, Z., Chen, X., Gill, T. M., Ma, C., Crimmins, E. M., & Levine, M. E. (2019). Associations of genetics,
485	behaviors, and life course circumstances with a novel aging and healthspan measure:
486	Evidence from the Health and Retirement Study. <i>PLoS Med, 16</i> (6), e1002827. doi:
487	10.1371/journal.pmed.1002827
488	Liu, Z., Kuo, P. L., Horvath, S., Crimmins, E., Ferrucci, L., & Levine, M. (2018). A new aging measure

489	captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A
490	cohort study. <i>PLoS Med, 15</i> (12), e1002718. doi: 10.1371/journal.pmed.1002718
491	Lourida, I., Hannon, E., Littlejohns, T. J., Langa, K. M., Hyppönen, E., Kuzma, E., & Llewellyn, D. J. (2019).
492	Association of Lifestyle and Genetic Risk With Incidence of Dementia. Jama, 322(5), 430-437.
493	doi: 10.1001/jama.2019.9879
494	Ma, Z., Zhu, C., Wang, H., Ji, M., Huang, Y., Wei, X., Shen, H. (2023). Association between biological
495	aging and lung cancer risk: Cohort study and Mendelian randomization analysis. iScience,
496	26(3), 106018. doi: 10.1016/j.isci.2023.106018
497	Mak, J. K. L., McMurran, C. E., Kuja-Halkola, R., Hall, P., Czene, K., Jylhava, J., & Hagg, S. (2023). Clinical
498	biomarker-based biological aging and risk of cancer in the UK Biobank. Br J Cancer, 129(1),
499	94-103. doi: 10.1038/s41416-023-02288-w
500	Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T. T. J., Havulinna, A. S., Lindbohm, J. V., Ripatti, S.
501	(2020). Polygenic and clinical risk scores and their impact on age at onset and prediction of
502	cardiometabolic diseases and common cancers. <i>Nat Med, 26</i> (4), 549-557. doi:
503	10.1038/s41591-020-0800-0
504	Mavaddat, N., Pharoah, P. D., Michailidou, K., Tyrer, J., Brook, M. N., Bolla, M. K., Garcia-Closas, M.
505	(2015). Prediction of breast cancer risk based on profiling with common genetic variants. J
506	<i>Natl Cancer Inst, 107</i> (5). doi: 10.1093/jnci/djv036
507	Rutledge, J., Oh, H., & Wyss-Coray, T. (2022). Measuring biological age using omics data. Nat Rev Genet,
508	23(12), 715-727. doi: 10.1038/s41576-022-00511-7
509	Schneider, C. V., Schneider, K. M., Teumer, A., Rudolph, K. L., Hartmann, D., Rader, D. J., & Strnad, P.
510	(2022). Association of Telomere Length With Risk of Disease and Mortality. JAMA Intern Med,
511	182(3), 291-300. doi: 10.1001/jamainternmed.2021.7804
512	Shams-White, M. M., Brockton, N. T., Mitrou, P., Romaguera, D., Brown, S., Bender, A., Reedy, J.
513	(2019). Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer
514	Research (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System.
515	<i>Nutrients, 11</i> (7). doi: 10.3390/nu11071572
516	Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA Cancer J Clin, 68(1), 7-30. doi:
517	10.3322/caac.21442
518	van Dongen, J., Nivard, M. G., Willemsen, G., Hottenga, J. J., Helmer, Q., Dolan, C. V., Boomsma, D. I.
519	(2016). Genetic and environmental influences interact with age and sex in shaping the human
520	methylome. <i>Nat Commun, 7,</i> 11115. doi: 10.1038/ncomms11115
521	Zhang, D., Leeuwenburgh, C., Zhou, D., Gong, Y., Pahor, M., Licht, J. D., & Braithwaite, D. (2022).
522	Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death
523	in Cancer Survivors. <i>JAMA Netw Open, 5</i> (6), e2218183. doi:
524	10.1001/jamanetworkopen.2022.18183
525	Zhu, M., Wang, T., Huang, Y., Zhao, X., Ding, Y., Zhu, M., Shen, H. (2021).Genetic Risk for Overall
526	Cancer and the Benefit of Adherence to a Healthy Lifestyle. <i>Cancer Res, 81</i> (17), 4618-4627.
527	doi: 10.1158/0008-5472.Can-21-0836
528	

	Men (n= 173431)		Women (1	n= 201032)
	Biologically younger n=81242	Biologically older n=92189	Biologically younger n=123648	Biologically older n=77384
PhenoAgeAccel, median (IQR), years	-2.61 (-4.351.25)	3.28 (1.50-6.06)	-3.55 (-5.641.81)	3.07 (1.33-5.79)
Age at baseline, median (IQR), years	57.00 (49.00-62.00)	58.00 (50.00-64.00)	58.00 (51.00-63.00)	56.00 (48.00-62.00)
Height, median (IQR), centimeters	176.00 (171.00-181.00)	175.00 (171.00-180.00)	162.50 (158.00-167.00)	162.00 (158.00-166.50)
Townsend deprivation index, median (IQR)	-2.34 (-3.76-0.16)	-1.86 (-3.52-1.10)	-2.33 (-3.73-0.07)	-1.79 (-3.44-1.10)
Family history of cancer, n (%)				
No	53907 (66.35)	60654 (65.79)	79800 (64.54)	50924 (65.81)
Yes	27335 (33.65)	31535 (34.21)	43848 (35.46)	26460 (34.19)
Healthy lifestyle factors, n (%)				
No current smoking	46412 (57.13)	43216 (46.88)	78743 (63.68)	45416 (58.69)
No alcohol consumption	2064 (2.54)	2828 (3.07)	6221 (5.03)	5459 (7.05)
Normal BMI	66120 (81.39)	62654 (67.96)	103054 (83.34)	49003 (63.32)
Regular physical activity	54346 (66.89)	57733 (62.62)	80629 (65.21)	46468 (60.05)
Healthy diet	18540 (22.82)	15486 (16.80)	39547 (31.98)	19826 (25.62)
Healthy lifestyle ^a , n (%)				
Favorable	7781 (9.58)	5255 (5.70)	17781 (14.38)	7178 (9.28)
Intermediate	57683 (71.00)	57489 (62.36)	87272 (70.58)	49324 (63.74)
Unfavorable	15778 (19.42)	29445 (31.94)	18595 (15.04)	20882 (26.98)
Albumin, median (IQR), (g/L)	46.20 (44.62-47.85)	44.95 (43.28-46.64)	45.47 (43.87-47.12)	44.04 (42.42-45.70)
Alkaline phosphatase, median (IQR), (U/L)	75.00 (64.30-87.40)	82.80 (70.10-97.90)	78.70 (65.10-93.90)	86.20 (70.60-104.00)
Creatinine, median (IQR), (umol/L)	77.60 (70.90-84.70)	82.50 (74.40-91.60)	61.70 (56.00-67.90)	65.50 (58.90-73.20)
Glucose, median (IQR), (mmol/l)	4.82 (4.49-5.14)	5.09 (4.72-5.60)	4.84 (4.54-5.14)	5.05 (4.70-5.55)

529 Table 1. Baseline characteristics of participants stratified by PhenoAgeAccel categories

C-reactive protein, median (IQR), (mg/dL)	0.09 (0.05-0.16)	0.19 (0.10-0.36)	0.10 (0.05-0.20)	0.25 (0.12-0.51)
Lymphocyte percent, median (IQR), (%)	29.86 (25.48-34.48)	25.60 (21.22-30.24)	31.09 (26.58-35.80)	27.00 (22.62-31.61)
Mean cell volume, median (IQR), (fL)	90.90 (88.46-93.30)	91.90 (89.10-94.74)	91.10 (88.60-93.54)	90.98 (87.64-94.02)
Red cell distribution width, median (IQR), (%)	13.01 (12.70-13.37)	13.63 (13.21-14.11)	13.10 (12.71-13.50)	13.90 (13.40-14.55)
White blood cell count, median (IQR), (1000 cells/uL)	6.12 (5.29-7.10)	7.27 (6.17-8.51)	6.24 (5.37-7.26)	7.41 (6.30-8.73)

^a Healthy lifestyle was defined as favorable (4-5 healthy lifestyle factors), intermediate (2-3 healthy lifestyle factors), and unfavorable (0-1 healthy lifestyle

531 factor).

				Model	1 ^a	Model	2 ^b
		N (cases)	Person-Years	HR (95% CI)	P value	HR (95% CI)	P value
	Per 5 years increase	173431 (11532)	1190628	1.15 (1.13-1.17)	1.55×10 ⁻⁵⁴	1.13 (1.11-1.15)	5.46×10 ⁻⁴⁴
	Category						
	Biologically younger	81242 (4649)	564818	Ref.		Ref.	
	Biologically older	92189 (6883)	625810	1.22 (1.18-1.27)	5.31×10 ⁻²⁶	1.19 (1.15-1.24)	3.18×10 ⁻²⁰
Men	Quintiles ^c						
	Low	34687 (1864)	242519	Ref.		Ref.	
	Intermediate	104058 (6668)	716312	1.15 (1.09-1.21)	2.17×10 ⁻⁷	1.12 (1.07-1.18)	8.01×10 ⁻⁶
	High	34686 (3000)	231797	1.44 (1.36-1.53)	1.01×10^{-34}	1.39 (1.31-1.47)	1.99×10 ⁻²⁷
	P for trend			3.03×10 ⁻³⁷		1.65×10 ⁻²⁹	
	Per 5 years increase	201032 (10838)	1393562	1.15 (1.13-1.17)	1.80×10 ⁻⁵³	1.13 (1.11-1.15)	1.35×10 ⁻⁴¹
	Category						
	Biologically younger	123648 (6229)	861570	Ref.		Ref.	
	Biologically older	77384 (4609)	531993	1.26 (1.22-1.31)	5.91×10 ⁻³³	1.23 (1.18-1.28)	2.71×10 ⁻²⁵
Women	Quintiles ^c						
	Low	40207 (1946)	281912	Ref.		Ref.	
	Intermediate	120618 (6351)	836341	1.15 (1.09-1.21)	1.46×10 ⁻⁷	1.13 (1.07-1.18)	5.89×10 ⁻⁶
	High	40207 (2541)	275309	1.46 (1.38-1.55)	2.54×10 ⁻³⁶	1.40 (1.32-1.49)	5.94×10 ⁻²⁸
	P for trend			4.23×10^{-37}		1.36×10^{-28}	

532 Table 2. Association between PhenoAgeAccel and cancer risk

^a Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal

534 components of ancestry.

^b Cox proportional hazards regression adjusted for Model 1, as well as cancer polygenic risk score and healthy lifestyle.

^c Defined by quintiles of PhenoAgeAccel: low (the bottom quintile), intermediate (quintiles 2-4) and high (the top quintile).

537 Abbreviations: CI, confidence interval; HR, hazards ratio; Ref, reference.

8		0	8 8		8				
		Low ger	Low genetic risk		Intermediate genetic risk		High genetic risk		
Gender	PhenoAgeAccel category	Biologically younger	Biologically older	Biologically younger	Biologically older	Biologically younger	Biologically older		
Gender Men Women	No. of cases/Person years	668/114962	1031/124526	2606/338950	4012/376782	1375/110907	1840/124502		
	Hazards ratio (95% CI)	Ref.	1.29 (1.17-1.42)	Ref.	1.27 (1.21-1.33)	Ref.	1.10 (1.02-1.18)		
	P value		3.53×10 ⁻⁷		3.15×10 ⁻²¹		1.07×10 ⁻²		
	Absolute risk (%)- 5 years (95% CI)	2.71 (2.49-2.94)	3.87 (3.60-4.14)	3.57 (3.41-3.72)	4.95 (4.78-5.13)	5.78 (5.44-6.11)	6.90 (6.55-7.26)		
	Absolute risk increase (%)- 5 years (95% CI)	Ref.	1.16 (0.84-1.46)	Ref.	1.39 (1.19-1.60)	Ref.	1.13 (0.68-1.52)		
	No. of cases/Person years	1030/173195	761/106937	3579/518611	2704/318753	1620/169764	1144/106303		
	Hazards ratio (95% CI)	Ref.	1.25 (1.14-1.38)	Ref.	1.30 (1.24-1.37)	Ref.	1.19 (1.10-1.28)		
Women	<i>P</i> value		2.65×10 ⁻⁶		1.84×10^{-24}		8.19×10 ⁻⁶		
W Onlen	Absolute risk (%) - 5 years (95% CI)	2.83 (2.63-3.02)	3.39 (3.12-3.65)	3.27 (3.15-3.39)	4.02 (3.86-4.19)	4.58 (4.33-4.83)	5.17 (4.84-5.49)		
	Absolute risk increase (%)- 5 years (95% CI)	Ref.	0.56 (0.26-0.86)	Ref.	0.76 (0.57-0.93)	Ref.	0.59 (0.23-0.98)		

538 Table 3. Risk of incident cancer according to PhenoAgeAccel categories within each genetic risk level ^a

^a Cox proportional hazards regression is adjusted for age, height, family history of cancer, Townsed deprivation index, height and the first 10 principal

540 components of ancestry.

541 Abbreviations: CI, confidence interval; Ref, reference.

542 Figure legends

543 Figure 1. Association results of PhenoAgeAccel with site-specific cancer risk per

5 years increased. Cox proportional hazards regression adjusted for age, height,
 cancer family history, Townsend deprivation index at recruitment, and the first 10

546 principal components of ancestry.

547

548 Figure 2. Effect of PhenoAgeAccel on the risk of incident cancer in the UK

549 Biobank. The distrubution of PhenoAgeAccel between participants with incident

- cancer and those without incident cancer in the UK Biobank for men(A) and women
- (B). Participants in the UK Biobank were divided into ten equal groups according to
- the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each
- group were compared with those in the bottom decile of PhenoAgeAccel. Error bars
- are 95% CIs. Standardized rates of cancer events in younger and older PhenoAge
- groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were
- estimated using Cox proportional hazard models with adjustment for age, height,
- 557 family history of cancer, Townsend deprivation index, and the first 10 principal
- components of ancestry. Shaded areas are 95% CIs.
- 559

560 Figure 3. Risk of incident cancer according to genetic and PhenoAgeAccel

- 561 categories in the UK Biobank for men (A) and women (B). The HRs were
- sestimated using Cox proportional hazard models with adjustment for age, height,
- family history of cancer, Townsend deprivation index, and the first 10 principal
- components of ancestry. Participants were divided into younger and older PhenoAge
- 565 under different genetic risk groups.
- 566

567 Figure 4. Absolute risk estimates of overall cancer based on the UK Biobank for

568 men (A) and women (B). The x-axis is chronological age. The curves describe

solution average risk of participants in younger and older PhenoAge groups. The dashed curve

- represents the average risk of the whole population in different ages. The red
- borizontal dotted line represents 2% of 5-year absolute risks of overall cancer.
- 572

Cancer site (ICD-10 code)	No. of cases/Person years	HR (95% CI)	<i>P</i> value
Lip, Oral Cavity, Pharynx (C00-C14)		
Men	296/1220540 —	■ 1.16 (1.04-1.29)	0.01
Women	149/1424826 —	1.11 (0.96-1.30)	0.17
Oesophagus (C15)			
Men	323/1220758	—— 1.45 (1.32-1.59)	1.12×10 ⁻¹⁵
Women	110/1425048 -	1.26 (1.07-1.49)	0.01
Stomach (C16)		, , , , , , , , , , , , , , , , , , ,	
Men	209/1220987	1.35 (1.20-1.52)	3.91×10 ⁻⁷
Women	83/1425127 -	1.27 (1.05-1.54)	0.01
Colon, Rectum (C18-C20)			
Men	1502/1217112	1 .21 (1.15-1.27)	1.64×10 ⁻¹⁵
Women	1121/1422055	► 1.12 (1.06-1.18)	9.96×10 ⁻⁵
Pancreas (C25)			0.000 10
Men	287/1221125	1 29 (1 17-1 44)	1 16×10-6
Women	231/1425010		1 14×10-5
Lung Bronchus Trachea (C33-C34	1)	- 1.20 (1.10 1.40)	1.14410
Mon	944/1220097		1 11~10-62
Memon	944/1220097		2.47×10-28
Skin Malanama (C42)	810/1423936	1.39 (1.31-1.47)	2.47×10 20
Skin Melanoma (C43)	E 4 E /1 01 0 7 1 0	0.00 (0.00 1.07)	0.00
Men	545/1219/10	0.98 (0.90-1.07)	0.08
women	600/1423192	1.00 (0.92-1.08)	0.97
Breast (C50)			1 50 100
women	4553/1409789	1.07 (1.04-1.10)	1.52×10⁵
Cervix Uteri (C53)		_	
Women	59/1425046 —	1.27 (1.01-1.60)	0.04
Corpus Uteri, NOS (C54-C55)			
Women	724/1422850	 1.27 (1.19-1.36)	2.99×10 ⁻¹³
Ovary (C56)			
Women	476/1423963 —	► 1.10 (1.00-1.20)	0.04
Prostate (C61)			
Men	4736/1206048	0.94 (0.91-0.96)	1.42×10⁻⁵
Testis (C62)			
Men	58/1221139	1.14 (0.88-1.49)	0.32
Kidney (C64)			
Men	401/1220361	—— 1.26 (1.15-1.38)	3.07×10-7
Women	217/1424679	——— 1.57 (1.41-1.74)	1.86×10 ⁻¹⁶
Bladder (C67)			
Men	399/1220186 -	1.17 (1.06-1.28)	1.14×10 ⁻³
Women	125/1424878	——— 1.39 (1.20-1.61)	9.07×10-6
Brain, Central Nerves (C70-C72)			
Men	226/1221108 —	I → 1.13 (1.00-1.28)	0.05
Women	154/1425069 —	0.95 (0.81-1.12)	0.52
Thyroid (C73)			
Men	53/1221160	0.98 (0.75-1.30)	0.91
Women	145/1424740 —		0.46
Hodgkin's Disease (C81)		· · · · ·	
Men	37/1221245 —	1.34 (1.01-1.78)	0.04
Women	29/1425138	1.37 (0.99-1.88)	0.05
Multiple Myeloma (C90)		- (/	
Men	201/1220867 —	1,16 (1.01-1.32)	0.03
Women	156/1424868		0.02
Lymphoid Leukaemia (C91)			3.02
Men	195/1220782	1 20 (1 14-1 47)	7 72×10-5
Women	128/142/821		0.01
women			0.01
	0.5 1.0	1.5 2.0	



Subgroup	No. of cases/ Total no.	Incidence/ 100,000 py		HR (95% CI)	P value
Low genetic risk					
Biologically younger	668/16458	581.06	•	Reference	Reference
Biologically older	1031/18229	827.94	-	1.30 (1.18-1.43)	1.22×10 ⁻⁷
Intermediate genetic risk					
Biologically younger	2606/48636	768.85		1.29 (1.18-1.40)	6.45×10 ⁻⁹
Biologically older	4012/55421	1064.81		1.64 (1.51-1.78)	1.02×10 ⁻³¹
High genetic risk					
Biologically younger	1375/16148	1239.78	-	2.11 (1.92-2.31)	1.09×10 ⁻⁵⁵
Biologically older	1840/18539	1477.89	-	2.29 (2.10-2.51)	1.33×10 ⁻⁷⁴
		0.5	1.0 2.0	4.0	

В

Subgroup	No. of cases/ Total no.	Incidence/ 100,000 py		HR (95% CI)	P value
Low genetic risk					
Biologically younger	1030/24736	594.71		Reference	Reference
Biologically older	761/15471	711.64		1.25(1.14-1.38)	2.14×10 ⁻⁶
Intermediate genetic risk					
Biologically younger	3579/74310	690.11		1.17(1.09-1.25)	9.55×10 ⁻⁶
Biologically older	2704/46308	848.31		1.52(1.41-1.63)	4.61×10 ⁻³⁰
High genetic risk					
Biologically younger	1620/24602	954.27		1.63(1.51-1.77)	1.03×10^{-34}
Biologically older	1144/15605	1076.17	-	1.94(1.78-2.11)	1.85×10 ⁻⁵³
		0.5	1.0 2.0	4.0	

